Fang, Zhen
Li, Peijuan
Du, Fengying
Shang, Liang
Li, Leping
Funding for this research was provided by:
National Natural Science Foundation of China (82203854)
Key Technology Research and Development Program of Shandong (2019JZZY010104)
Special Foundation for Taishan Scholars Program of Shandong Province (ts20190978)
Academic promotion programme of Shandong First Medical University (2019QL021)
Article History
Received: 17 April 2023
Accepted: 30 July 2023
First Online: 3 August 2023
Declarations
:
: The authors declare no competing interests.
: Three-dimensional (3D); Patient-derived tumor organoids (PDTOs); Extracellular Matrix (ECM); Engelbreth-Holm-Swarm (EHS); Mesenchymal stem cells (MSC); Induced Pluripotent Stem Cells (iPSCs); EGF, Noggin, R-spondin (ENR); Colorectal cancer (CRC); Embryonic stem cells (ESCs); Adult stem cells (ASCs); Human pluripotent stem cell (hPSC); Circulating tumor cells (CTCs); Patient Derived Organoid (PDO); Rhabdomyosarcomas (RMS); Tumor-infiltrating lymphocytes (TILs); Food and Drug Administration (FDA); β-hydroxybutyrate (BHB); Cancer-associated fibroblasts (CAFs).
: Not applicable.
: Not applicable.